[go: up one dir, main page]

MXPA04001388A - Expandable gastric retention device. - Google Patents

Expandable gastric retention device.

Info

Publication number
MXPA04001388A
MXPA04001388A MXPA04001388A MXPA04001388A MXPA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A
Authority
MX
Mexico
Prior art keywords
gastric retention
retention device
expandable gastric
expandable
therapeutics
Prior art date
Application number
MXPA04001388A
Other languages
Spanish (es)
Inventor
W Ayres James
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Publication of MXPA04001388A publication Critical patent/MXPA04001388A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

The present application concerns gastric retention devices formed from compositions comprising polymeric materials, such as polysaccharides, and optional additional materials including excipients, therapeutics, and diagnostics, that reside in the stomach for a controlled and prolonged period of time.
MXPA04001388A 2001-08-16 2001-10-22 Expandable gastric retention device. MXPA04001388A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31307801P 2001-08-16 2001-08-16
PCT/US2001/046146 WO2003015745A1 (en) 2001-08-16 2001-10-22 Expandable gastric retention device

Publications (1)

Publication Number Publication Date
MXPA04001388A true MXPA04001388A (en) 2004-05-27

Family

ID=23214285

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001388A MXPA04001388A (en) 2001-08-16 2001-10-22 Expandable gastric retention device.

Country Status (14)

Country Link
EP (1) EP1416914A1 (en)
JP (1) JP2005501097A (en)
KR (1) KR20040032918A (en)
CN (1) CN1543337A (en)
BR (1) BR0117123A (en)
CA (1) CA2456976A1 (en)
CO (1) CO5670360A2 (en)
IL (1) IL160363A0 (en)
MX (1) MXPA04001388A (en)
NO (1) NO20040611L (en)
NZ (1) NZ531461A (en)
PL (1) PL368327A1 (en)
WO (1) WO2003015745A1 (en)
ZA (1) ZA200402066B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458328B1 (en) 2001-11-21 2013-01-30 Bracco Diagnostics Inc. Formulations comprising locust bean gum as stabilizing agent and mannitol as osmotic agent for use in medical or diagnostic procedures
EP1701705A4 (en) * 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp IMPROVED ABSORPTION OF MODIFIED RELEASE DOSAGE FORMS
US7699863B2 (en) 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
EP2046397A2 (en) * 2006-07-19 2009-04-15 SmithKline Beecham Corporation Method for radiolabeling formulations for gamma scintigraphy assesment
CN102552103B (en) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 Lamivudine solid dispersion, and preparation method, pharmaceutical composition and use of the dispersion
DK2858604T3 (en) 2012-06-07 2024-05-21 Epitomee Medical Ltd EXPANDED DEVICE
US11129793B2 (en) 2013-12-05 2021-09-28 Epitomee Medical Ltd Retentive devices and systems for in-situ release of pharmaceutical active agents
US10413507B2 (en) 2014-06-11 2019-09-17 Massachusetts Institute Of Technology Enteric elastomers
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
JP2018515476A (en) 2015-05-01 2018-06-14 マサチューセッツ インスティテュート オブ テクノロジー Inducible shape memory guidance device
EP3364946A4 (en) 2015-10-23 2019-06-26 Lyndra, Inc. GASTRIC-RESISTANT SYSTEMS FOR PROLONGED RELEASE OF THERAPEUTIC AGENTS AND METHODS OF USE THEREOF
WO2017100367A1 (en) 2015-12-08 2017-06-15 Lyndra, Inc. Geometric configurations for gastric residence systems
CA3025650A1 (en) 2016-05-27 2017-11-30 Lyndra, Inc. Materials architecture for gastric residence systems
CA3038557A1 (en) 2016-09-30 2018-04-05 Lyndra, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
US11337919B2 (en) * 2017-12-18 2022-05-24 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release
TR201914116A2 (en) * 2019-09-17 2021-04-21 Univ Yeditepe PRODUCTION METHOD OF NATURAL BIOMATERIALS AND CRYOGELS AND THE USE OF THESE CRYOGELS AS SOFT TISSUE SCACHE OR DRUG CARRIER SYSTEM
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
DE4406424A1 (en) * 1994-02-28 1995-08-31 Bayer Ag Expandable dosage forms
JP2001527023A (en) * 1997-08-11 2001-12-25 アルザ・コーポレーション Extended release active dosage form adapted for gastric retention
ATE245414T1 (en) * 1998-09-14 2003-08-15 Ranbaxy Lab Ltd ORAL ADMINISTERED SYSTEM FOR TEMPORAL AND SPATIAL CONTROLLED MEDICINAL DELIVERY
JP2000256216A (en) * 1999-03-04 2000-09-19 Meiji Milk Prod Co Ltd Gel composition
EP1305021A4 (en) * 2000-06-23 2009-09-23 Teva Pharma Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Also Published As

Publication number Publication date
CN1543337A (en) 2004-11-03
IL160363A0 (en) 2004-07-25
NO20040611L (en) 2004-04-16
ZA200402066B (en) 2005-05-09
JP2005501097A (en) 2005-01-13
BR0117123A (en) 2004-09-28
EP1416914A1 (en) 2004-05-12
CA2456976A1 (en) 2003-02-27
KR20040032918A (en) 2004-04-17
WO2003015745A1 (en) 2003-02-27
PL368327A1 (en) 2005-03-21
NZ531461A (en) 2008-03-28
CO5670360A2 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
WO2005079384A3 (en) Expandable gastric retention device
MXPA04001388A (en) Expandable gastric retention device.
IL144147A0 (en) Regulators of the pct or smoothened pathway, compositions and uses related thereto
MXPA02008398A (en) High early-strength cementitious composition.
AU6872201A (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
MXPA03002070A (en) Contraception process and administration form for the same.
ZA200003998B (en) Pharmaceutical compositions.
AP1703A (en) Heparin-derived polysaccharide mixtures, preparation method and pharmaceutical compositions containing same.
DE602004025338D1 (en) POLYMERIZABLE COMPOUND, COPOLYMERS, COMPOSITION THEREIN, PICTURE PRODUCTION METHOD AND IMAGE GENERATING DEVICE
HUP0401811A2 (en) Medicinal composition improved in solubility in water and process for its preparation
MXPA03004932A (en) Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors.
RS97604A (en) New etonogestrel esters
ZA200210359B (en) Pharmaceutical compositions.
MX233159B (en) Fabric treatment composition.
MXPA03000624A (en) Compositions and films for capsule manufacture.
IL171875A0 (en) Pioglitazone salts,such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
IL157065A0 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
AU4324301A (en) Oxazolidinone tablet formulation
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
GB0118368D0 (en) Light-emmisive polymer blends and light-emissive devices made from the same
AU2002210491A1 (en) Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof
HUP0204422A3 (en) Calcium dicarboxylate ethers, methods of making the compounds, and pharmaceutical compositions containing them
GB0428306D0 (en) Compound
ATE323493T1 (en) CONTROLLED RELEASE OF ANTIDEPRESSANTS
MXPA03005217A (en) Application devices.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal